Dr. Ann Eapen Division of Hematology/Oncology: UC Irvine discusses Adverse Effects of Venetoclax and Ibrutinib Only 1 in 50 Patients had Tumor Lysis Syndrome at MOASCs Spotlight On Hematology in Huntington Beach 2018.
Adverse Effects of Venetoclax and Ibrutinib Only 1 in 50 Patients had Tumor Lysis Syndrome
